New Zealand Markets open in 2 hrs 36 mins

BIIB Jan 2024 270.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
70.720.00 (0.00%)
As of 09:41AM EST. Market open.
Full screen
Loading interactive chart…
  • Financial Times

    Japan’s Eisai aims to silence critics over breakthrough Alzheimer’s drug

    Just weeks ago at the company’s headquarters, Haruo Naito, the 74-year-old chief executive of Japan’s Eisai, was feeling vindicated after almost four decades of trying to develop an Alzheimer’s drug. Ahead of the release of detailed information on Eisai’s new drug lecanemab, developed with Biogen, the company’s share price surged 60 per cent after results of a late-stage clinical trial showed that it slowed the progression rate of the memory-degenerating disease. Initial results published by Eisai in September raised hopes of a new treatment for a disease that pharmaceutical companies have spent billions of dollars over several decades researching, only to be disappointed by repeated failures.

  • Bloomberg

    Eisai, Biogen Plunge After Report of Second Death in Groundbreaking Alzheimer’s Drug Trial

    (Bloomberg) -- Eisai Co shares fell the most in about 16 months following a report of a second death potentially linked to the groundbreaking experimental drug for Alzheimer’s disease it’s developing with Biogen Inc.Most Read from BloombergApple to Lose 6 Million iPhone Pros From Tumult at China PlantNext Covid-19 Strain May be More Dangerous, Lab Study ShowsMusk Threatens War With Apple, Jeopardizing Vital RelationshipStocks Hit by Fedspeak as China Woes Boost Havens: Markets WrapThe case invol

  • Financial Times

    Dementia/Biogen: causal controversy means investors must take a stance

    Dementia drug candidates still have one of the highest failure rates in clinical development — 97 per cent according to one study. Shares in Biogen fell 4.5 per cent on Monday after the website Science reported the early death of an Alzheimer’s disease patient participating in trials of lecanemab. The US biotech has been developing the treatment with Eisai of Japan.